Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

Abstract

CONTEXT The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen. The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme. OBJECTIVE To determine whether CYP2D6 variation is… (More)
DOI: 10.1001/jama.2009.1420

Topics

7 Figures and Tables

Cite this paper

@article{Schroth2009AssociationBC, title={Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.}, author={Werner Schroth and Matthew P. Goetz and Ute Hamann and Peter A. Fasching and Marcus Schmidt and Stefan Winter and Peter Fritz and Wolfgang E. Simon and Vera J. Suman and Matthew Ames and Stephanie L. Safgren and Mary J. Kuffel and Hans Ulrich Ulmer and Julia Bol{\"a}nder and Reiner Strick and Matthias W. Beckmann and H. K{\"{o}lbl and Richard M. Weinshilboum and James N. Ingle and Michel F Eichelbaum and Matthias Schwab and Hiltrud Brauch}, journal={JAMA}, year={2009}, volume={302 13}, pages={1429-36} }